BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition

Tyrosine kinase inhibitors (TKI) are widely used to treat patients with leukemia driven by BCR-ABL11 and other oncogenic tyrosine kinases2,3. Recent efforts focused on the development of more potent TKI that also inhibit mutant tyrosine kinases4,5. However, even effective TKI typically fail to eradi...

Descripción completa

Detalles Bibliográficos
Autores principales: Duy, Cihangir, Hurtz, Christian, Shojaee, Seyedmehdi, Cerchietti, Leandro, Geng, Huimin, Swaminathan, Srividya, Klemm, Lars, Kweon, Soo-mi, Nahar, Rahul, Braig, Melanie, Park, Eugene, Kim, Yong-mi, Hofmann, Wolf-Karsten, Herzog, Sebastian, Jumaa, Hassan, Koeffler, H Phillip, Yu, J. Jessica, Heisterkamp, Nora, Graeber, Thomas G., Wu, Hong, Ye, B. Hilda, Melnick, Ari, Müschen, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597744/
https://www.ncbi.nlm.nih.gov/pubmed/21593872
http://dx.doi.org/10.1038/nature09883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597744/
https://www.ncbi.nlm.nih.gov/pubmed/21593872
http://dx.doi.org/10.1038/nature09883

Ejemplares similares